Reata Inks $45M Deal With Investors Over Failed Drug
Reata has inked a $45 million settlement to resolve claims it misled investors by not disclosing the U.S. Food and Drug Administration's misgivings about the company's trial of a kidney drug,...To view the full article, register now.
Already a subscriber? Click here to view full article